Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA ...
Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...
In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal ...
Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.
Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
The vaccine maker posted a loss of $2.91 per share for the quarter, exceeding analysts' estimates of a $2.73 per share loss.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...